<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0413066</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2830</journal-id>
<journal-id journal-id-type="nlm-ta">Cell</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell</journal-id>
<journal-title-group>
<journal-title>Cell</journal-title>
</journal-title-group>
<issn pub-type="ppub">0092-8674</issn>
<issn pub-type="epub">1097-4172</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28431241</article-id>
<article-id pub-id-type="pmc">5546324</article-id>
<article-id pub-id-type="doi">10.1016/j.cell.2017.04.001</article-id>
<article-id pub-id-type="manuscript">NIHMS866088</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>AKT/PKB Signaling: Navigating the Network</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Manning</surname>
<given-names>Brendan D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Toker</surname>
<given-names>Alex</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, MA</aff>
<aff id="A2">
<label>2</label>Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, and Ludwig Center at Harvard, Boston, MA</aff>
<author-notes>
<corresp id="FN1">Correspondence to: <email>bmanning@hsph.harvard.edu</email> and <email>atoker@bidmc.harvard.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>12</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>20</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>4</month>
<year>2018</year>
</pub-date>
<volume>169</volume>
<issue>3</issue>
<fpage>381</fpage>
<lpage>405</lpage>
<!--elocation-id from pubmed: 10.1016/j.cell.2017.04.001-->
<abstract>
<p id="P2">The Ser/Thr kinase AKT, also known as protein kinase B (PKB), was discovered 25 years ago and has been the focus of tens of thousands of studies in diverse fields of biology and medicine. There have been many advances in our knowledge of the upstream regulatory inputs into AKT, key multifunctional downstream signaling nodes (GSK3, FoxO, mTORC1), which greatly expand the functional repertoire of Akt, and the complex circuitry of this dynamically branching and looping signaling network that is ubiquitous to nearly every cell in our body. Mouse and human genetic studies have also revealed physiological roles for the AKT network in nearly every organ system. Our comprehension of AKT regulation and functions is particularly important given the consequences of AKT dysfunction in diverse pathological settings, including developmental and overgrowth syndromes, cancer, cardiovascular disease, insulin resistance and type-2 diabetes, inflammatory and autoimmune disorders, and neurological disorders. There has also been much progress in developing AKT-selective small molecule inhibitors. Improved understanding of the molecular wiring of the AKT signaling network continues to make an impact that cuts across most disciplines of the biomedical sciences.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>